Effects of sodium‐glucose co‐transporter‐2 inhibitors by background cardiovascular medications: A systematic review and meta‐analysis
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15200 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Ioannis Avgerinos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Hyperkalemia, Heart Failure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aim
To explore whether the beneficial cardiovascular (CV) effect of sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors is consistent with or without concurrent use of CV medications in patients with type 2 diabetes, heart failure (HF) or chronic kidney disease.
Methods
We searched Medline and Embase up to September 2022 for CV outcomes trials. The primary endpoint was the composite of cardiovascular (CV) death or hospitalization for HF. Secondary outcomes included the individual components of CV death, hospitalization for HF, death from any cause, major adverse CV events or renal events, volume depletion and hyperkalaemia. We pooled hazard ratios (HRs) and risk ratios alongside 95% confidence intervals (CIs).
Results
We included 12 trials comprising 83 804 patients. SGLT‐2 inhibitors reduced the risk of CV death or hospitalization for HF regardless of background use of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs), angiotensin receptor‐neprilysin inhibitors (ARNIs), b‐blockers, diuretics, mineralocorticoid receptor antagonists (MRAs), or triple combination therapy of either an ACEI/ARB plus b‐blocker plus MRA, or an ARNI plus b‐blocker plus MRA (HRs ranged from 0.61 to 0.83; P > .1 for each subgroup interaction). Similarly, no subgroup differences were evident for most analyses for the secondary outcomes of CV death, hospitalization for HF, all‐cause mortality, major adverse CV or renal events, hyperkalaemia and volume depletion rate.
Conclusions
The benefit of SGLT‐2 inhibitors seems to be additive to background use of CV medications in a broad population of patients. These findings should be interpreted as hypothesis generating because most of the subgroups analysed were not prespecified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Diabetes Centre, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK.
- Harris Manchester College, University of Oxford, Oxford, UK.
ORCID-Profile: Ioannis Avgerinos, Thomas Karagiannis, David R Matthews, Apostolos Tsapas, Eleni Bekiari
Zitieren
APA
Avgerinos, I., Karagiannis, T., Matthews, D. R., Tsapas, A., & Bekiari, E. (2023). Effects of sodium‐glucose co‐transporter‐2 inhibitors by background cardiovascular medications: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15200
Vancouver
Avgerinos I, Karagiannis T, Matthews DR, Tsapas A, Bekiari E. Effects of sodium‐glucose co‐transporter‐2 inhibitors by background cardiovascular medications: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15200
BibTeX
@article{Avgerinos2023,
author = {Avgerinos, Ioannis and Karagiannis, Thomas and Matthews, David R and Tsapas, Apostolos and Bekiari, Eleni},
title = {Effects of sodium‐glucose co‐transporter‐2 inhibitors by background cardiovascular medications: A systematic review and meta‐analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15200}
}
EUVIMED